Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Traws Pharma, Inc.ONTX · Entity 8032 | CHIEF MEDICAL OFFICER | March 13, 2023 | March 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Traws Pharma, Inc.
Report date March 13, 2023 · Filed March 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2033-03-13 | Direct | 62,000 |
Reported balance
After 2023-03-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-13 · Grant · Acquired 62,000 · Balance 62,000 F1: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,667 |
Reported balance
After 2023-03-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-13 · Grant · Acquired 20,667 · Balance 20,667 F2: Each restricted stock unit is convertible into one share of common stock. F3: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.
F2: Each restricted stock unit is convertible into one share of common stock.
F3: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2023 Filed Mar 14, 2023 22:46 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantRestricted Stock Units · Derivative | 20,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-004865 · form4-03142023_100352.xml · derivative · entry 2 Gelder Mark S. MD · CIK 0001564390 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,667 Underlying: Common Stock · 20,667 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit is convertible into one share of common stock. F3 · derivative.exercise_date: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary F3 · derivative.expiration_date: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 22:46 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 62,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001415889-23-004865 · form4-03142023_100352.xml · derivative · entry 1 Gelder Mark S. MD · CIK 0001564390 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2033-03-13 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| February 07, 2023 Filed Feb 8, 2023 22:58 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionRestricted Stock Units · Derivative | 5,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002168 · form4-02082023_100255.xml · derivative · entry 3 Gelder Mark S. MD · CIK 0001564390 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,667 Underlying: Common Stock · 5,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On February 7, 2022 the reporting person was granted 17,500 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary. F2 · derivative.expiration_date: On February 7, 2022 the reporting person was granted 17,500 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary. Read SEC document |
| February 07, 2023 Filed Feb 8, 2023 22:58 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Tax withholdingCommon Stock | 1,242 | $1.36 | $1,689.12 |
DisclosureSEC source: 0001415889-23-002168 · form4-02082023_100255.xml · nonDerivative · entry 2 Gelder Mark S. MD · CIK 0001564390 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,487 Read SEC document |
| February 07, 2023 Filed Feb 8, 2023 22:58 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionCommon Stock | 5,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-002168 · form4-02082023_100255.xml · nonDerivative · entry 1 Gelder Mark S. MD · CIK 0001564390 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 03, 2022 Filed Aug 4, 2022 20:34 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Tax withholdingCommon Stock | 1,135 | $1.32 | $1,498.20 |
DisclosureSEC source: 0001415889-22-008260 · form4-08042022_010823.xml · nonDerivative · entry 2 Gelder Mark S. MD · CIK 0001564390 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,896 Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:34 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionRestricted Stock Units · Derivative | 4,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008260 · form4-08042022_010823.xml · derivative · entry 3 Gelder Mark S. MD · CIK 0001564390 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,300 Underlying: Common Stock · 4,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 2, 2021 the reporting person was granted 13,950 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. F2 · derivative.expiration_date: On August 2, 2021 the reporting person was granted 13,950 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:34 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionCommon Stock | 4,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-008260 · form4-08042022_010823.xml · nonDerivative · entry 1 Gelder Mark S. MD · CIK 0001564390 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 21:52 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantRestricted Stock Units · Derivative | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000964 · edgar.xml · derivative · entry 2 Gelder Mark S. MD · CIK 0001564390 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common stock · 17,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit is convertible into one share of common stock. F2 · derivative.exercise_date: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. F2 · derivative.expiration_date: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 21:52 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 51,750 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001179110-22-000964 · edgar.xml · derivative · entry 1 Gelder Mark S. MD · CIK 0001564390 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,750 Underlying: Common stock · 51,750 shares Expires 2032-02-07 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| September 28, 2021 Filed Sep 29, 2021 12:25 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 2,381 | $4.20 | $10,000.20 |
DisclosureSEC source: 0001179110-21-008981 · edgar.xml · nonDerivative · entry 1 Gelder Mark S. MD · CIK 0001564390 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,381 Read SEC document |
| August 02, 2021 Filed Aug 5, 2021 00:02 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantRestricted Stock Units · Derivative | 13,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-007924 · edgar.xml · derivative · entry 2 Gelder Mark S. MD · CIK 0001564390 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,950 Underlying: Common stock · 13,950 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit is convertible into one share of common stock. F2 · derivative.exercise_date: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. F2 · derivative.expiration_date: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. Read SEC document |
| August 02, 2021 Filed Aug 5, 2021 00:02 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 41,825 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001179110-21-007924 · edgar.xml · derivative · entry 1 Gelder Mark S. MD · CIK 0001564390 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,825 Underlying: Common stock · 41,825 shares Expires 2031-08-02 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 23:46 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 20,000 | $0.00 Strike: $7.56 | $0.00 |
DisclosureSEC source: 0001179110-21-006842 · edgar.xml · derivative · entry 1 Gelder Mark S. MD · CIK 0001564390 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: Theses options vest over 4 years, 25% on the first anniversary of the grant and thereafter in 36 equal monthly installments over the next 3 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.